Find a Clinical Trial
Filter
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
Multi-spectral imaging
Ovarian cancer
Female
18-99
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)
Endometrial cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center